← Back to Clinical Trials
Recruiting NCT06516432

NCT06516432 Parasternal Blockade and Serum Lactate in Cardiac Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06516432
Status Recruiting
Phase
Sponsor Instituto Mexicano del Seguro Social
Condition Elective Cardiac Surgery
Study Type INTERVENTIONAL
Enrollment 86 participants
Start Date 2024-01-01
Primary Completion 2024-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Parasternal blockRequirement of total dose regarding fentanyl

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 86 participants in total. It began in 2024-01-01 with a primary completion date of 2024-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Serum lactate level is a key indicator of tissue perfusion. Parasternal blockade is associated with reduced postoperative inflammatory response by inhibiting stress response, leading to better outcomes. Elevated lactate levels help identify patients at risk of postoperative morbidity and mortality. This analytical cross-sectional study evaluated the association between parasternal blockade and serum lactate levels in patients undergoing elective cardiac surgery in 2022 at Specialty Hospital CMNO. Patients with and without parasternal block were compared for changes in serum lactate levels during and after anesthesia within the first 24 hours.

Eligibility Criteria

Inclusion Criteria: * Adult patients older than 18 years * Either sex * ASA II-III * Patients who underwent cardiac surgery with median sternotomy and use of cardiopulmonary bypass. Exclusion Criteria: * Patients with pre-existing conditions that could independently affect serum lactate levels.

Contact & Investigator

Central Contact

Alejandro Gonzalez, 3

✉ avygail5@gmail.com

📞 3331294165

Principal Investigator

Alejandro Gonzalez, 3

PRINCIPAL INVESTIGATOR

IMSS

Frequently Asked Questions

Who can join the NCT06516432 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Elective Cardiac Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06516432 currently recruiting?

Yes, NCT06516432 is actively recruiting participants. Contact the research team at avygail5@gmail.com for enrollment information.

Where is the NCT06516432 trial being conducted?

This trial is being conducted at Guadalajara, Mexico.

Who is sponsoring the NCT06516432 clinical trial?

NCT06516432 is sponsored by Instituto Mexicano del Seguro Social. The principal investigator is Alejandro Gonzalez, 3 at IMSS. The trial plans to enroll 86 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology